Immunogenicity of E2CD154 Subunit Vaccine Candidate against Classical Swine Fever in Piglets with Different Levels of Maternally Derived Antibodies

• Main Authors: Yusmel Sordo-Puga, Danny Pérez-Pérez, Carlos Montero-Espinosa, Aymé Oliva-Cárdenas, Iliana Sosa-Teste, Carlos A. Duarte, María Pilar Rodríguez-Moltó, Talía Sardina-González, Elaine Santana-Rodríguez, Milagros Vargas-Hernández, Yaneris Cabrera-Otaño, Julio A. Ancizar-Fragoso, Yohandy Fuentes-Rodríguez, Mario Pablo Estrada, Marisela Suárez-Pedroso
• Format: Article
• Language: English
• Published: MDPI AG 2021-12-01
• Series: Vaccines
• Subjects: classical swine fever virus; E2CD154; maternally derived antibodies; subunit vaccine candidate
• Online Access: https://www.mdpi.com/2076-393X/9/1/7

E2CD154 is a novel subunit vaccine candidate against classical swine fever virus (CSFV). It contains the E2 envelope protein from CSFV fused to the porcine CD154 molecule formulated in the oil adjuvant Montanide^TM ISA50 V2. Previous works evidenced the safety and immunogenicity of this candidate. Here, two other important parameters related to vaccine efficacy were assessed. First, the existence of high maternally derived antibody (MDA) titers in piglets born to sows vaccinated with E2CD154 was demonstrated. These MDA titers remained above 1:200 during the first seven weeks of life. To assess whether the titers interfere with active vaccination, 79 piglets from sows immunized with either E2CD154 or a modified live vaccine were vaccinated with E2CD154 following a 0–21-day biphasic schedule. Animals immunized at either 15, 21, or 33 days of age responded to vaccination by eliciting protective neutralizing antibody (NAb) titers higher than 1:600, with a geometric mean of 1:4335, one week after the booster. Those protective levels of NAb were sustained up to six months of age. No vaccination-related adverse effects were described. As a conclusion, E2CD154 is able to induce protective NAb in piglets with different MDA levels and at different days of age.